- ISIN
- US35168W1036
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Feb 2, 2024
Highlights
- Market Cap
- $137.73M
- Enterprise Value
- $140.52M
- EPS (TTM)
- -$1.24
- Gross Profit (TTM)
- -$569.00K
- EBITDA (TTM)
- -$114.95M
- Year Range
- $0.38 - $2.45
- Target Price
- $5.00
- ROA (TTM)
- -108.67%
- ROE (TTM)
- -505.22%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
GUTS Performance Chart
Fractyl Health, Inc (GUTS) is down 60.5% since the beginning of the year. At $1 per share, GUTS is trading 64.5% below its 52-week high of $2.
Loading charts...
Returns By Period
Fractyl Health, Inc (GUTS) has returned -60.50% so far this year and -59.39% over the past 12 months.
Fractyl Health, Inc
- 1D
- 1.25%
- 1M
- -4.46%
- YTD
- -60.50%
- 6M
- -61.89%
- 1Y
- -59.39%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
GUTS Monthly Returns History
Based on dividend-adjusted daily data since Feb 2, 2024, GUTS's average daily return is -0.16%, while the average monthly return is -3.36%.
Historically, 41% of months were positive and 59% were negative. The best month was Sep 2025 with a return of +63.7%, while the worst month was Jan 2026 at -79.1%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 6 months.
On a daily basis, GUTS closed higher 45% of trading days. The best single day was Jun 9, 2025 with a return of +44.7%, while the worst single day was Jan 29, 2026 at -68.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -79.09% | 2.02% | -2.45% | 39.25% | 26.46% | 7.79% | -60.50% | ||||||
| 2025 | -10.68% | -15.22% | -23.72% | 6.72% | 49.61% | -14.74% | 13.58% | -47.22% | 63.71% | -22.64% | 27.64% | 40.13% | 6.80% |
| 2024 | -34.55% | -17.78% | -8.65% | -0.30% | -36.65% | -25.29% | 9.72% | -27.71% | 11.26% | -9.06% | -19.53% | -85.02% |
Benchmark Metrics
Fractyl Health, Inc has an annualized alpha of -46.91%, beta of 1.20, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since February 02, 2024.
- This stock participated in 72.83% of S&P 500 Index downside but only -157.16% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -46.91%
- Beta
- 1.20
- R²
- 0.03
- Upside Capture
- -157.16%
- Downside Capture
- 72.83%
Return for Risk
Risk / Return Rank
GUTS ranks 25 for risk / return — below 25% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Fractyl Health, Inc (GUTS) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| GUTS | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.51 | ||
| Sortino ratioReturn per unit of downside risk | -2.62 | ||
| Omega ratioGain probability vs. loss probability | 1.02 | 1.37 | -0.34 |
| Calmar ratioReturn relative to maximum drawdown | -0.71 | 2.78 | -3.50 |
| Martin ratioReturn relative to average drawdown | -1.12 | 12.44 | -13.56 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Fractyl Health, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Fractyl Health, Inc was 97.14%, occurring on Feb 17, 2026. The portfolio has not yet recovered.
The current Fractyl Health, Inc drawdown is 93.68%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -97.14%Feb 2026 | 2y 16d | — | 2y 4moFeb 2024 - now |
Drawdown Indicators
| GUTS | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.14% | -56.78% | -40.36% |
Max Drawdown (1Y)Largest decline over 1 year | -83.43% | -9.10% | -74.33% |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -93.68% | -1.80% | -91.88% |
Average DrawdownAverage peak-to-trough decline | -80.88% | -10.71% | -70.17% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 54.51% | 2.03% | +52.48% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Fractyl Health, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Fractyl Health, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for GUTS in comparison with other companies in the Biotechnology industry. Currently, GUTS has a P/B value of 6.4. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with GUTS
Add Fractyl Health, Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with GUTS